These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 18182612)
1. Federal drug agency gets flack about human subjects protections in clinical trials. Beckman M J Natl Cancer Inst; 2008 Jan; 100(2):90-1. PubMed ID: 18182612 [No Abstract] [Full Text] [Related]
2. Individual researcher liability for clinical research on humans. Miller RK J Biolaw Bus; 2003; 6(2):8-16. PubMed ID: 14682365 [TBL] [Abstract][Full Text] [Related]
3. Ethics. Human health research ethics. Silbergeld E; Lerman S; Hushka L Science; 2004 Aug; 305(5686):949. PubMed ID: 15310879 [No Abstract] [Full Text] [Related]
4. [Ethics committees in USA--background and development. Responsible conductors of clinical trials required for risk minimization]. Lund LH Lakartidningen; 2008 Jan 9-15; 105(1-2):42-4. PubMed ID: 18293746 [No Abstract] [Full Text] [Related]
5. The basics of human subjects protection. Yoder LH Medsurg Nurs; 2006 Apr; 15(2):95-8; quiz 99. PubMed ID: 16700248 [No Abstract] [Full Text] [Related]
6. Ethical human-research protections: not universal and not uniform. Fleming DA; Reynolds D Am J Bioeth; 2008 Nov; 8(11):21-2. PubMed ID: 19061102 [No Abstract] [Full Text] [Related]
7. Clinical trials and public trust. Kennedy D Science; 2004 Dec; 306(5702):1649. PubMed ID: 15576574 [No Abstract] [Full Text] [Related]
8. Protection of research subjects. Pesando JM N Engl J Med; 2003 Jul; 349(2):188-92; author reply 188-92. PubMed ID: 12856655 [No Abstract] [Full Text] [Related]
9. Continued concern: human subject protection, the institutional review board, and continuing review. Hoffman S Tenn Law Rev; 2001; 68(4):725-70. PubMed ID: 16189912 [No Abstract] [Full Text] [Related]
10. Response to open peer commentaries on "Social contexts influence ethical considerations of research". Levine RJ; Gordon JB; Mazure CM; Rubin PE; Schaller BR; Young JL Am J Bioeth; 2011 May; 11(5):W1-2. PubMed ID: 21534134 [No Abstract] [Full Text] [Related]
11. Who watches the watchmen? Nature; 2011 Aug; 476(7359):125. PubMed ID: 21833048 [No Abstract] [Full Text] [Related]
12. [Take-over of the risk-benefit by the clinical study subject and its regulation]. Antal J Orv Hetil; 2005 Jun; 146(26):1399-404. PubMed ID: 16052982 [TBL] [Abstract][Full Text] [Related]
13. Risking the rewards of regulation. Schwab AP Am J Bioeth; 2008 Nov; 8(11):9-10. PubMed ID: 19061096 [No Abstract] [Full Text] [Related]
14. Case study: agency says institutional review board (IRB) failed to warn subjects of significant problems. Maloney DM Hum Res Rep; 2006 Mar; 21(3):6-7. PubMed ID: 16789303 [No Abstract] [Full Text] [Related]
15. Recruiting human subjects without IRB review/approval. Maloney DM Hum Res Rep; 2002 Aug; 17(8):3. PubMed ID: 12731493 [No Abstract] [Full Text] [Related]
16. Federal case is settled over death of research subject. Maloney DM Hum Res Rep; 2005 Apr; 20(4):1-2. PubMed ID: 16018114 [No Abstract] [Full Text] [Related]
17. Ethical and scientific implications of the globalization of clinical research. Andrews CA N Engl J Med; 2009 Jun; 360(26):2793; author reply 2793. PubMed ID: 19557890 [No Abstract] [Full Text] [Related]
18. Trials and tribulations. Gilbert S Hastings Cent Rep; 2008; 38(2):14-8. PubMed ID: 18457222 [No Abstract] [Full Text] [Related]
19. Protection of research subjects. Tremaine WJ N Engl J Med; 2003 Jul; 349(2):188-92; author reply 188-92. PubMed ID: 12856652 [No Abstract] [Full Text] [Related]
20. Central IRBs: why are some institutions reluctant to sign on? McNeil C J Natl Cancer Inst; 2005 Jul; 97(13):953-5. PubMed ID: 15998943 [No Abstract] [Full Text] [Related] [Next] [New Search]